Robust and accurate respiratory drug delivery
This article was originally published in Start Up
The forthcoming patent cliff will provide a range of generic product opportunities in the respiratory drug market, and there are still unmet needs for formulations that deliver inhaled drugs safely, reliably and accurately. This has created an opportunity for Prosonix Ltd. By providing sophisticated control of the fundamental physiochemical properties of drug particles by design-first intent, Prosonix aims to engineer better respiratory medicines that work irrespective of choice of device.
You may also be interested in...
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.